$25m US-funded study goes beyond testing Ebola vaccine
This article was originally published in Scrip
Executive Summary
A large-scale trial being run by the Centers for Disease Control and Prevention (CDC) testing an experimental monovalent recombinant vesicular stomatitis virus (rVSV) Ebola vaccine from NewLink and its partner Merck is underway in earnest in Sierra Leone, with more than 200 people already enrolled, 90 of whom have been vaccinated, a top official from the US health agency told reporters on 14 April.